The European Medicines Agency (EMA), along with the European Commission and the Member States of the European Union (EU), has proposed changes in guidelines for first-in-human clinical trials.
The changes in guidelines are intended to improve the safety of the volunteers participating in the trials.
Go deeper with GlobalData
EMA recently released a concept paper seeking public consultation on the revisions to be made on the existing guidelines.
The proposition has been taken to accommodate the evolving clinical practices in the last ten years, as well as take into account the incident occurring in the phase I first-in-human clinical trial in France in January, which claimed one person and hospitalised five subjects.
The guidance is primarily focused on non-clinical aspects, such as the better integration of pharmacokinetic along with pharmacodynamic data and toxicological testing into the overall risk assessment, as well as the role of non-clinical data in the definition of the estimated therapeutic dose, maximal dose, and dose steps and intervals.
See Also:
It also stresses clinical aspects such as criteria to stop a study, the rolling review of emerging data with special reference to safety information for trial participants, and the handling of adverse events in relation to stopping rules and rules guiding progress to the next dosing level.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEMA is aiming to publish the final revised guideline to conduct first-in-human clinical trials early next year.
